Last updated on July 2019

Pharmacokinetic Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency


Brief description of study

The purpose of the study is to investigate pharmacokinetics, efficacy and safety of BT524 in patients with congenital fibrinogen deficiency.

Detailed Study Description

The present study is designed as a prospective, open-label, multicentre, phase I/III study investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524 following intravenous administration in the treatment or prophylaxis of bleeding in patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia.

Clinical Study Identifier: NCT02065882

Find a site near you

Start Over

Site 11

Cairo, Egypt
  Connect »

Site 07

Gießen, Germany
  Connect »

Site 04

Avellino, Italy
  Connect »

Site 03

Milan, Italy
  Connect »

Site 05

Padua, Italy
  Connect »

Site 06

Palermo, Italy
  Connect »

Site 01

Beirut, Lebanon
  Connect »

Site 02

Beirut, Lebanon
  Connect »

Site12

Tunis, Tunisia
  Connect »

Site 07

Gießen, Germany
  Connect »